Breaking News

A2A Pharmaceuticals Collaborates with Laxai Life Sciences

Will co-develop SARS-CoV-2 main proteases inhibitors for the treatment of COVID-19.

By: Contract Pharma

Contract Pharma Staff

A2A Pharmaceuticals, a biotechnology company committed to the advancement of scientific research and new therapeutic agents, has signed an agreement to co-develop SARS-CoV-2 Main Proteases inhibitors for the treatment of COVID-19 with Laxai Life Sciences Pvt. Ltd.   Under this collaboration, A2A designed the molecules using its proprietary computational AI-enabled drug discovery platform Sculpt, which are currently being synthesized and will be evaluated by Laxai. Both parties will collaborate i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters